AdjuTec Pharma enters phase I with novel AMR treatment

AdjuTec Pharma has launched a phase I clinical trial for its leading candidate, APC148, targeting a critical unmet need in combating antimicrobial resistance.

This move into human trials is a significant milestone in demonstrating the safety and therapeutic potential of APC148, positioning AdjuTec as a key player in the fight against high-priority drug-resistant infections.